Treatment and Prognosis of Isolated Local Relapse after Stereotactic Body Radiotherapy for Clinical Stage I Non-Small-Cell Lung Cancer Importance of Salvage Surgery

被引:42
作者
Hamaji, Masatsugu [1 ]
Chen, Fengshi [1 ]
Matsuo, Yukinori [2 ]
Ueki, Nami [2 ]
Hiraoka, Masahiro [2 ]
Date, Hiroshi [1 ]
机构
[1] Kyoto Univ, Grad Sch Med, Dept Thorac Surg, Kyoto 6068507, Japan
[2] Kyoto Univ, Grad Sch Med, Dept Radiat Oncol & Image Appl Therapy, Kyoto 6068507, Japan
基金
日本学术振兴会;
关键词
Non-small-cell lung cancer; Surgery; Radiotherapy; Chemotherapy; POSITRON-EMISSION-TOMOGRAPHY; RADIATION-THERAPY; ABLATIVE RADIOTHERAPY; THORACOSCOPIC LOBECTOMY; TUMOR RECURRENCE; F-18-FDG PET/CT; HIGH-RISK; RESECTION; FAILURE; OUTCOMES;
D O I
10.1097/JTO.0000000000000662
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Many efforts have been made to detect local relapse (LR) in the follow-up after stereotactic body radiotherapy (SBRT) for non-small-cell lung cancer (NSCLC) although limited data are available on its treatment and prognosis. We aimed to characterize treatment options and clarify long-term outcomes of isolated LR after SBRT for patients with clinical stage I NSCLC. Methods: We reviewed our institutional database in search of patients with isolated LR after SBRT for clinical stage I NSCLC at our institution between 1999 and 2013. Patient characteristics were compared with Mann-Whitney U test, (2) test, or Fisher's exact test as appropriate. Survival outcomes were estimated with Kaplan-Meier method. Potential prognostic factors were investigated using Cox proportional hazard model. Results: Of 308 patients undergoing SBRT for clinical stage I NSCLC, 49 patients were identified to have isolated LR. Twelve patients underwent salvage surgery, none underwent radiotherapy, and eight patients received chemotherapy, whereas 29 patients received best supportive care. No patient characteristic except operability was significantly related with patient selection for LR treatments. Five-year overall survival (OS) rate of the whole cohort was 47.9% from SBRT and 25.7% from LR. Salvage surgery was associated with improved OS after LR (p = 0.014), and 5-year OS for patients undergoing salvage surgery was 79.5% from LR. Conclusions: It was confirmed that our patient selection for salvage surgery for isolated LR was associated with favorable survival outcomes. Operability based on multidisciplinary conferences, rather than measurable patient characteristics, is essential for appropriate patient selection for salvage surgery.
引用
收藏
页码:1616 / 1624
页数:9
相关论文
共 50 条
  • [21] Patient-reported Outcomes After the Treatment of Early Stage Non-small-cell Lung Cancer With Stereotactic Body Radiotherapy Compared With Surgery
    Alberts, Leonie
    Wolff, Henri B.
    Kastelijn, Elisabeth A.
    Lagerwaard, Frank J.
    Hofman, Frederik N.
    El Sharouni, Sherif Y.
    Schramel, Franz M. N. H.
    Coupe, Veerle M. H.
    CLINICAL LUNG CANCER, 2019, 20 (05) : 370 - +
  • [22] Stereotactic Radiotherapy for Stage I Small Cell Lung Cancer
    Verma, Vivek
    Simone, Charles B., II
    Zhen, Weining
    ONCOLOGIST, 2016, 21 (02) : 131 - 133
  • [23] Treatment for Elderly Patients with Clinical Stage I Non-Small Cell Lung Cancer; Surgery or Stereotactic Body Radiotherapy?
    Miyazaki, Talcum
    Yamazaki, Takuya
    Nakamura, Daisuke
    Yamasaki, Naoya
    Tsuchiya, Tomoshi
    Matsumoto, Keitaro
    Kamohara, Ryotaro
    Hatachi, Go
    Nagayasu, Takeshi
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S782 - S782
  • [24] QUALITY OF LIFE AFTER STEREOTACTIC RADIOTHERAPY FOR STAGE I NON-SMALL-CELL LUNG CANCER
    van Zyp, Noelle C. van der Voort
    Prevost, Jean-Briac
    van der Holt, Bronno
    Braat, Cora
    van Klaveren, Robertus J.
    Pattynama, Peter M.
    Levendag, Peter C.
    Nuyttens, Joost J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 77 (01): : 31 - 37
  • [25] Stereotactic body radiotherapy for stage I non-small cell lung cancer
    Martel-Lafay, I.
    ONCOLOGIE, 2012, 14 (05) : 282 - 288
  • [26] CURATIVE TREATMENT OF STAGE I NON-SMALL-CELL LUNG CANCER IN PATIENTS WITH SEVERE COPD: STEREOTACTIC RADIOTHERAPY OUTCOMES AND SYSTEMATIC REVIEW
    Palma, David
    Lagerwaard, Frank
    Rodrigues, George
    Haasbeek, Cornelis
    Senan, Suresh
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 82 (03): : 1149 - 1156
  • [27] Stereotactic Body Radiotherapy (SBRT) with Lower Doses for Selected Patients with Stage I Non-small-cell Lung Cancer (NSCLC)
    Janssen, Stefan
    Kaesmann, Lukas
    Rudat, Volker
    Rades, Dirk
    LUNG, 2016, 194 (02) : 291 - 294
  • [29] Nodal recurrence after stereotactic body radiotherapy for early stage non-small cell lung cancer: Incidence and proposed risk factors
    Wink, Krista C. J.
    van Baardwijk, Angela
    Troost, Esther G. C.
    De Ruysscher, Dirk
    CANCER TREATMENT REVIEWS, 2017, 56 : 8 - 15
  • [30] Definition of stereotactic body radiotherapy Principles and practice for the treatment of stage I non-small cell lung cancer
    Guckenberger, M.
    Andratschke, N.
    Alheit, H.
    Holy, R.
    Moustakis, C.
    Nestle, U.
    Sauer, O.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2014, 190 (01) : 26 - 33